Kiniksa Pharmaceuticals International (KNSA) closed at $77.09 on Oct 6, 2026, up 1.0% on the day. The stock is down 1.1% over the past month, up 19.0% over three months, up 86.9% year to date and up 100.3% over the past year. It trades 7.1% below its 52-week high of $82.94 and 119.0% above its 52-week low of $35.20. The close sits below its 50-day moving average ($77.54) and above its 200-day moving average ($56.57).
KNSA is scheduled to report earnings on Oct 26, 2026.
KNSA options were pricing 56% at-the-money implied volatility on Oct 12, 2026, an IV rank of 52 over the past year.
Kiniksa Pharmaceuticals International is scheduled to report on Oct 26, 2026.
Yes — the Oct 6, 2026 close of $77.09 is 36.3% above the 200-day average of $56.57.
KNSA closed 7.1% below its 52-week high of $82.94.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
